Search

Your search keyword '"Slater Emily P"' showing total 13 results
Start Over Author "Slater Emily P" Publisher wiley
13 results on '"Slater Emily P"'

1. Mesenteric fibrosis in patients with small intestinal neuroendocrine tumors is associated with enrichment of alpha‐smooth muscle actin‐positive fibrosis and COMP‐expressing stromal cells

Author

Graf, Sebastian D., primary, Keber, Corinna U., additional, Hattesohl, Akira, additional, Teply‐Szymanski, Julia, additional, Hattesohl, Sophia, additional, Guder, Marc, additional, Gercke, Norman, additional, Di Fazio, Pietro, additional, Slater, Emily P., additional, Jesinghaus, Moritz, additional, Denkert, Carsten, additional, Bartsch, Detlef K., additional, and Lehman, Bettina, additional

Published
2024
Full Text
View/download PDF

2. Dissecting the role of toll‐like receptor 7 in pancreatic cancer

Author

Stark, Maren, primary, Nicolai, Marina, additional, Tatura, Marina, additional, Keber, Corinna U., additional, Kaufmann, Andreas, additional, Chung, Ho‐Ryun, additional, Slater, Emily P., additional, Heeschen, Christopher, additional, Lawlor, Rita T., additional, Scarpa, Aldo, additional, Bartsch, Detlef K., additional, Gress, Thomas M., additional, Bauer, Stefan, additional, and Buchholz, Malte, additional

Published
2023
Full Text
View/download PDF

3. Incidental findings in pancreas screening programs for high‐risk individuals: Results from three European expert centers

Author

Ibrahim, Isaura S, primary, Brückner, Catharina, additional, Carrato, Alfredo, additional, Earl, Julie, additional, Inderson, Akin, additional, Vos tot Nederveen Cappel, Wouter H, additional, Mintziras, Ioannis, additional, Matthäi, Elvira, additional, Figiel, Jens, additional, Wasser, Martin, additional, Moreau, Hans, additional, Bonsing, Bert, additional, Slater, Emily P, additional, Bartsch, Detlef K, additional, and Vasen, Hans FA, additional

Published
2019
Full Text
View/download PDF

7. RNASEL germline variants are associated with pancreatic cancer

Author

Bartsch, Detlef K., primary, Fendrich, Volker, additional, Slater, Emily P., additional, Sina‐Frey, Mercedes, additional, Rieder, Harald, additional, Greenhalf, William, additional, Chaloupka, Brunhilde, additional, Hahn, Stephan A., additional, Neoptolemos, John P., additional, and Kress, Ralf, additional

Published
2005
Full Text
View/download PDF

13. Pancreatic cancer screening is effective in individuals at risk with predisposing germline gene variants, but not in gene variant-negative familial pancreatic cancer families.

Author

Maurer E, Lehman B, Matthäi E, Denzer U, Figiel J, Jesinghaus M, Slater EP, Stefenelli U, Gress TM, and Bartsch DK

Subjects
Humans, Male, Female, Middle Aged, Germany, Adult, Prospective Studies, Carcinoma, Pancreatic Ductal genetics, Carcinoma, Pancreatic Ductal diagnosis, Carcinoma, Pancreatic Ductal diagnostic imaging, Aged, Adenocarcinoma genetics, Adenocarcinoma diagnosis, Adenocarcinoma diagnostic imaging, Risk Factors, Carcinoma, Pancreatic Neoplasms genetics, Pancreatic Neoplasms diagnosis, Pancreatic Neoplasms diagnostic imaging, Early Detection of Cancer methods, Genetic Predisposition to Disease, Germ-Line Mutation, Magnetic Resonance Imaging, Endosonography
Abstract

Objective: To evaluate the diagnostic yield of pancreatic cancer screening in individuals at risk (IAR) from familial pancreatic cancer (FPC) families with respect to the presence or absence of pathogenic germline variants predisposing to pancreatic adenocarcinoma (PDAC)., Design: In a 20 years period, IAR from FPC families were enrolled in a prospective screening program of the national case collection for FPC of Germany, including magnet resonance imaging (MRI) and endoscopic ultrasound (EUS). The diagnostic yield was analyzed regarding significant pancreatic lesions such as PDAC, high-grade pancreatic-intraepithelial-neoplasia (PanIN3) and intraductal-papillary-mucinous-neoplasia (IPMN) with high-grade dysplasia. Screening results were compared between carriers of pathogenic variants and variant-negative IAR., Results: 337 IAR, including 74 (22%) variant-carriers and 263 IAR of variant-negative FPC families (mean age 49; standard deviation [SD] + 8.9) were followed 64 (SD + 55) months. IAR underwent 5.1 (SD + 3.9) screening visits with 1733 MRI (5.1,SD + 3.9 per IAR) and 728 EUS (2.2,SD + 1.7 per IAR). In 12 (4%) cases, significant pancreatic lesions were detected, including 4 PDAC, 3 PanIN3 and 5 high-grade IPMN. Three of 4 IAR with PDAC died after a mean of 27 months postoperatively, and one IAR is alive without evidence of disease after 31 months. The diagnostic yield for significant lesions was 13.5% (10/74) for variant carriers compared to 0.8% (2/263) for IAR of variant-negative FPC families (p < 0.001). Logistic regression analysis revealed that a negative variant status was almost always accompanied by the absence of a significant lesion over time with a negative predictive value of 99.2% (95% CI 97.3%-99.9%)., Conclusion: The diagnostic yield seems to justify PDAC screening in IAR of FPC-families with pathogenic germline variants in PDAC predisposing genes, not in IAR of variant-negative families., (© 2024 The Author(s). United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results